Virbac: volume-led growth is real, but the 18.8% margin flatters the run-rate

Virbac's half-year report, out September 17, headlines two numbers that pull in opposite directions the moment you read their labels. Revenue rose 7.4% at constant exchange rates and scope — the organic figure — and the adjusted EBIT margin hit 18.8%. Taken together they look like a clean acceleration for the French animal-health group, a steady mid-cap compounder in veterinary pharmaceuticals. Look closer, and the margin number flatters the business while the growth number understates it. Which one you trust decides what the stock is worth.

Growth is deeper than the reported print

The 7.4% is measured as if exchange rates and scope never moved. Convert those euros at the rates the company actually received and the top line rose just 4.0%. That gap is currency, not commerce — the business in local-currency terms grew more than three percentage points faster than the number on the income statement. For a U.S. investor the setup is the familiar one of a strong-dollar environment punishing a euro-reporting exporter.

And the growth underneath that organic figure is the encouraging kind. Volumes and mix contributed about +5.4%, while price added roughly +2%. For a pharmaceutical company to grow mostly from volume rather than price is a quality signal; it means demand, not just pricing, is carrying the load. The gain was also balanced: companion animals (pets) rose 10.0% while farm animals (livestock) rose 6.7%, and every region grew at constant rates — Europe +6.5%, North America +10.1%, international +7.5%. North America, historically the swing factor in Virbac's story, is again running at double digits.

The engine room is the "Supercharge" platform of priority growth ranges — with standout performance in its Mobility and Ruminants ranges — which grew about 12% excluding the acquired Thyronorm endocrinology franchise, which itself contributed another roughly 3.7 points. This is the pipeline that justifies the valuation, and it is behaving.

The margin needs a reality check

Now the number the headline celebrates. The 18.8% adjusted EBIT margin is a half-year figure, and Virbac's accounting seasons are lopsided: costs, marketing, research and development land disproportionately in the second half. The company itself still guides the full year 2026 to an adjusted operating margin of about 17%. That is not a coincidence of guidance-cautiousness — it is the same shape as 2025, when an 18.3% first half gave way to a 16.3% full year. The first half always runs hot; 18.8% is a real number but not the sustainable run-rate.

The bridge in this half is worth reading because it shows the mix strength is doing the work. Management credits favorable gross-margin mix for about +1 point, lower R&D intensity for -0.8 point, then hands roughly 1.3 points back to higher other operating costs tied to half-year phasing and one-offs. Net profit, at €87.1 million, grew only 5.9% — slower than the margin suggests, because currency bites the bottom line too via a €1.5 million foreign-exchange loss and other finance items.

Balance sheet stays disciplined. Net debt rose to €196 million from €173 million at year-end, almost entirely seasonal working capital, on an enterprise value near €2.8 billion — low leverage for a business of this stability. Cash generation for the year is guided near €80 million.

What the price already pays for

Fair value here is a judgment call the market has already made broadly. Virbac's market cap sits near €2.6 billion, and the shares trade around 17.5x trailing P/E and roughly 15x forward. For a business compounding organic sales in the high single digits with a mid-to-high-teen operating margin and low debt, that is a reasonable, not a cheap, multiple — a quality premium, not a distressed discount.

The strongest bear fact is that guidance is doing real work: hitting the upper end of the 5.5%–7.5% sales range and holding that ~17% margin depends on continued Supercharge momentum plus recently added franchises (Thyronorm, plus a distribution agreement with a purchase option for a cat kidney product and a transition toward marketing-authorization ownership for a canine heat-management product, both slated for 2027). Farm-animal growth has cooled from 8.4% in the first quarter to 6.7% in the half, and France and Belgium were flat on supply constraints — worth watching, not yet alarming. Currency is the other live variable: if the euro's headwind fades, reported growth snaps toward the higher organic rate, which is the single most direct path for the shares to re-rate.

This is a good company and a fairly priced stock. Nothing in the half makes it cheap enough to ignore, and nothing makes it fragile enough to avoid; the rating is closer to a hold than a strong conviction either way. The question that will settle it is the second half — whether the Supercharge engine keeps the 17% annual margin alive and whether the currency drag starts to lift. A reasonable investor already holding Virbac has a solid, compounding operator; anyone new is paying a fair price for quality and waiting on those two operating variables before the case gets firmer.